Company Analysis
Sign in

DNA X, Inc. (SONM)

Nasdaq: SONM · Telephone & Telegraph Apparatus · San Diego, CA · filing with the SEC since 2002
Full chart Alerts Compare
Grade2.5
◀ Past 3.8● Present 1.6▶ Future 2.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of DNA X, Inc.

Nine metrics read from its own filings, by tense
Headline grade
2.5/10
◀ Past3.830% of the headline
● Present1.640% of the headline
▶ Future2.430% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 7 read as filed from the record and 2 are SI estimates, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

3.8/1030% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
2.5/10

Has it survived what it has been through?

17 warning events since 2017; the latest 2026-08-14.

weight 33% of this tense · 25th percentile among 10 sector filers · read for itself

From the record

DNA X, Inc.'s filings since 2017 show 17 warning events of 3 kinds: a notice about its exchange listing (8-K item 3.01, 12 times, the latest 2026-05-27); an auditor change (8-K item 4.01, 2 times, the latest 2026-04-30); a late-report notice (Form NT 10-K or NT 10-Q, 3 times, the latest 2026-08-14) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
1.9/10

What has it actually done, year after year?

-15.1% a year over 7 filed years; profitable in 1 of 7.

weight 45% of this tense · 19th percentile among 10 sector filers · read for its customers

From the record

DNA X, Inc.'s 7 filed years say what it did: revenue went from $136 million in fiscal 2018 to $51 million in fiscal 2024, down 15.1% a year; it rose in 2 of 6 years; the deepest fall was 62% from fiscal 2018 to fiscal 2024; net income was positive in 1 of 7 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span-15.1%bottom 17% of its family
  • the share of years revenue rosebottom 20% of its family
  • the share of filed years with a profitbottom 5% of its family
  • the deepest fall from a revenue peak62.5%bottom 35% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
9.5/10

How has it treated the people who own it?

SI estimate 9.5/10, confidence 35 of 100 (one part).

weight 22% of this tense · 95th percentile among 10 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the top 5% of 10 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 10 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: DNA X, Inc.'s shareholder treatment is put at 9.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 5% of 10 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

1.6/1040% of the headline grade · 3 of 3 filed

Financial health

as filed
1.0/10

Is it financially healthy right now?

Leverage 118%: owes 118¢ per asset dollar.

weight 45% of this tense · 10th percentile among 10 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, DNA X, Inc.'s shareholders' equity was below zero, so the profit on it is not read. Leverage: it owed about 118 cents per dollar of assets, and net share issuance: its share count grew 175.7% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetsbottom 15% of its family
  • the share count against the year beforebottom 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
3.1/10

How strong is its position in its industry?

bottom 31% of 9 in its family; net margin -66.1%.

weight 33% of this tense · 31st percentile among 9 sector filers · read for its customers

From the record

DNA X, Inc.'s standing among 9 graded names in its industry family: revenue of $51 million in fiscal 2024 ranks in the bottom 28% by size; a net margin of -66.1% ranks in the bottom 6%; revenue growth of -2.3% a year over the last 3 filed years ranks in the top 39% (its annual reports).

What it rests on

  • revenue against the family$50.9Mbottom 28% of its family
  • net margin-66.1%bottom 6% of its family
  • three-year revenue growth-2.3%top 39% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
0.7/10

What are the people in charge doing?

bottom 7% of 8 in its family for leadership; chief executive since 2026.

weight 22% of this tense · 7th percentile among 8 sector filers · read for its shareholders

From the record

DNA X, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Mulica, Michael C (Acting CEO, as filed), filing under that title since 2026-02-10, 9 months (bottom 7% of its family); most of the 3 officers and directors filing now have filed since the record of its people begins (2022-07-13), a floor of 4.3 years the record cannot see past, so that part is not read; 14 officer or director changes were reported on Form 8-K since 2023-11-13, against the 3 people in charge now (bottom 6%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge14 in three years among 3 peoplebottom 6% of its family
  • the chief executive's years on the record10 monthsbottom 7% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

2.4/1030% of the headline grade · 2 of 3 filed, 1 estimated

Room to expand

SI estimate
0.5/10

How much room does it have to grow?

SI estimate 0.5/10, confidence 35 of 100 (one part).

weight 45% of this tense · 5th percentile among 10 sector filers · read for itself

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, cash less debt against assets, which ranks in the bottom 5% of 10 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
What the record cannot read
The record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue.
How it was reasoned
one part: cash less debt against assets, the one part on file, ranked among 10 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: DNA X, Inc.'s room to expand is put at 0.5 of 10 with a confidence of 35 of 100, because read from one part only, cash less debt against assets, which ranks in the bottom 5% of 10 in its family; the record does not carry two of the four parts: cash less debt against assets, cash from operations less capital spending against revenue, gross margin, research against revenue. A filing that carries the missing parts replaces this estimate with the filed reading.

Growth drivers

as filed
5.6/10

What could actually drive growth from here?

top 44% of 10 in its family for growth drivers.

weight 33% of this tense · 56th percentile among 10 sector filers · read for its customers

From the record

DNA X, Inc.'s growth drivers, from the filed years to fiscal 2024: revenue grew -2.3% a year over the last three filed years against -15.1% over all 7, speeding up (top 6% of its family); the newest year grew -45.6% (bottom 6%); research spending grew -7% a year (bottom 28%); capital spending grew 66.9% a year (top 5%) (its annual reports). DNA X, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span+12.8 points a yeartop 6% of its family
  • the newest year's revenue growth-45.6%bottom 6% of its family
  • three-year growth of research spending-7.0%bottom 28% of its family
  • three-year growth of capital spending66.9%top 5% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
1.5/10

Did its newest year beat what its own record pointed to?

bottom 15% of 9 in its family for expectations against reality.

weight 22% of this tense · 15th percentile among 9 sector filers · read for its shareholders

From the record

DNA X, Inc.'s newest year against its own record: revenue of $51 million in fiscal 2024 came in 58.5% below the $123 million its prior three years' pace pointed to (bottom 6% of its family); net income of $34 million against a prior three-year average of $18 million (bottom 35%); a net margin of -66.1% against -30.4% before (bottom 6%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace-58.5%bottom 6% of its family
  • net income against the prior three years' average-91%bottom 35% of its family
  • net margin against its prior average-35.7 pointsbottom 6% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton SONM · research, not advice